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Poster Session II S259values .0.9 were acceptable. Precision and mean bias\15% were
acceptable.
24 children (0.4-17.2 years) participated. Most patients (18) re-
ceived cyclosporine and methotrexate. Mean actual dose infusion
time was 1216 5.9 min. Mean AUC-all after the first cyclosporine
dose was 23976 713 hmg/L. Sufficient data were available to vali-
date the LSSs in 16 (3, 4 & 5-point LSSs) and 15 (6-point LSS) pa-
tients. Values of AUC predicted by all but the 5-point LSS were
strongly associated with AUC-all.
The 3-point LSS (2, 6 and 8 hours) is likely suitable for determin-
ing AUC following the first cyclosporine dose given as 2-hour infu-
sion to children undergoing HSCT. Further validation in a larger
number of patients is required. The relationship between acute
GVHD and cyclosporine AUC at different time periods after
HSCT merits further study.
Sample times Mean bias PrecisionAdjusted r2
(hours after start
of infusion) (%; range) (%)2, 6 and 8 0.9504 2 0.7 (213.7 to 12.4) 6.0
2, 2.5, 6 and 8 0.9547 22.7 (216.6 to 7.7) 6.0
2, 2.5, 4, 6 and 8 0.8896 24.7 (225.6 to 0.8) 9.1
2, 2.5, 4, 6, 8 and 10 0.9062 24.7 (224.2 to 20.1) 8.5274
KIDNEY INJURY (KI) IN PEDIATRIC RECIPIENTS OF ALLOGENEIC STEM
CELL TRANSPLANT (ALLOSCT): RISK OF KI IS GREATER WITH MYELOA-
BLATIVE CONDITIONING (MAC) THAN WITH REDUCED INTENSITY CON-
DITIONING (RIC) IN FIRST MONTH FOLLOWING ALLOSCT
Satwani, P.1, Bavishi, S.1, Jin, Z.2, Jacobson, J.S.3, Tallamy, B.1,
Cairo, M.S.1,4,5 1Columbia University, New York, NY; 2Columbia Uni-
versity, New York, NY; 3Columbia University, New York, NY; 4Colum-
bia University, New York, NY; 5Columbia University, New York, NY
Background:Pediatric alloSCTpatients are at substantial risk of de-
veloping KI, which contributes to transplant-related morbidity and
mortality (Holthe et al, Pediatr Nephrol., 2002).
Objective:To compare the incidence and outcomes of KI in pediat-
ric recipients following RIC vs. MAC AlloSCT in 1st year post-Al-
loSCT.
Methods: Among 170 pediatric patients, we used the Schwartz
equation to estimate creatinine clearance (eCCl) at# 2wks pre-
and 1,3,6,9 and 12 mo post-alloSCT with RIC orMAC.We catego-
rized patients whose eCCI dropped$ 50% from baseline as having
KI. Pts received Tacrolimus and MMF for GVHD prophylaxis
(Osunkwo/Cairo et al. BBMT, 2004). Other nephrotoxic exposures
included Ambisome at 3 mg/kg from day 0-100 (Roman/Cairo et al.
PBC, 2008) and CMV prophylaxis with Foscarnet/Ganciclovir
(Shereck/Cairo et al. PBC, 2007). Including risk factors significant
at 0.1 level based onc-square tests, we developedmultivariable logis-
tic regression models of predictors of kidney injury, and Cox models
of overall survival.
Results: 76 pts (median 10;0.3-22 yrs) receivedRIC-alloSCT; 94 pts
(median 8;0.3-22 yrs) receivedMA-AlloSCT. At 1 mo post alloSCT,
A total of43/94 (45.7%) MAC recipients but only 13/76 (17.1%)
RIC recipients had KI (p\0.0001). The two groups did not differ
in risk of KI at 3, 6, 9 or 12 months post-alloSCT. In univariate anal-
ysis, p-values were .0.1 for the association of KI at 1 mo with age,
sex, CMV at risk status, and fungal infections. Associations with
p-values #0.1were MAC (odds ratio {OR}-4.1, 95% CI 2.0-
8.4,p5 0.0001), poor disease risk status (OR-1.8,95% CI 0.8-4.0,
p5 0.1),VOD (OR-4.9, 95% CI 0.5-46.0, p5 0.1), and UCB
(OR-1.8,95% CI 0.9-3.6, p5 0.1). In logistic regression, only
MAC was an independent predictor of KI (OR-3.5, 95% CI 1.6-
7.7, p5 0.0001).
In the Cox model, all-cause mortality hazard ratios (HR) were:
RIC vs. MAC (HR5 0.3) p5 0.0007, poor vs. average risk disease
status (HR5 2.2) p5 0.002, UCB vs. MSD and MUD (HR-2.2)
p5 0.02, and KI vs. no KI (HR5 2.0) p5 0.006).Conclusions: In the firstmonth after alloSCT in children,MACwas
strongly associated with risk of KI, and overall, MAC and KI were
independent predictors of mortality. Avoiding KI in the first month
post-alloSCT might improve OS.275
SINGLE VS DOUBLE DOSE PALONOSETRON FOR THE PREVENTION OF
ACUTE AND DELAYED NAUSEA AND VOMITING IN PATIENTS UNDERGO-
ING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION
Marcacci, G., Becchimanzi, C., Capobianco, G., Arcamone, M.,
Corazzelli, G., Frigeri, F., Russo, F., Pinto, A. National Cancer Institute
‘‘Fondazione G. Pascale’’, Naples, Italy
Objectives:The vast majority of patients (pts) undergoing high dose
chemotherapy (HDT) and autologous stem cell transplantation
(ASCT) still experience major acute and delayed chemotherapy-in-
duced nausea and vomiting (CINV), showing how emesis control
in the ASCT setting remains sub-optimal. Palonosetron (PALO),
a new 5-hydroxytryptamine receptor antagonist with long half-life
and high receptor binding affinity, achieves a significant control of
CINV in pts receiving moderately/highly emetogenic chemother-
apy. We prospectively evaluated the efficacy of a single or double
i.v. dose PALO in pts undergoing HDT and ASCT.
Methods: A total of 60 pts (M/F5 32/28), median age 45 yrs (r16-
64), with diagnosis of lymphoma (29), myeloma (24), sarcoma (5),
acute leukemia (1), breast cancer (1) were accrued. The first cohort
(30 pts) received a single iv PALO dose (0.25 mg) plus 8 mg of dexa-
methasone (DMS) 30’ before starting of HDT while in the second
cohort (30 pts) the first dose was followed by a further PALO
(0.25 mg)/DMS (8 mg) injection 48 h after HDT. The distribution
of conditioning regimens (high-dose melphalan5 28, BEAM5 25,
MitoMel5 6, ThioEpiCTX5 1) was comparable between the two
cohorts. Acute (24 h) and delayed (120 h) CINV episodes were rated
by the visual analogic scale (MASCC/MAT) while CINV impact on
daily activities was self-assessed by pts (at 120 h from starting of
HDT), through the Functional Living Index-Emesis (FLIE) tool.
Results: No significant differences between the two groups (single
vs double PALO) emerged as to acute CINV evaluation (MAT) since
98% of pts achieved a complete response (CR5 no emesis, no need
for rescue therapy) with only 17 pts (28%) experiencing moderate
nausea (median intensity5 5, r1-10). Double-dose PALO displayed
a trend for a better control of delayed nausea which occurred in 53%
vs 77% of pts (p5 0.0581). In addition, double PALO dosing had
a highly significant impact on nausea-related modifications of daily
activities. FLIE nausea score was of a median value of 55.26
(r47.5-58.9) in pts receiving two doses of PALO vs 40.92 (r35-
45.2) for pts treated with the single PALO dosing (p5 0.0009).
Conclusion: Our results indicate that double dose PALO achieves
an optimal control of acute/delayed CINV and significantly reduces
the detrimental impact of nausea on daily activities in patients under-
going HDT. The impressive activity of PALO in the ASCT setting
might be possibly improved by combination with NK1 receptor an-
tagonists.276
END-OF-LIFE EXPERIENCE OF CHILDREN UNDERGOING STEM CELL
TRANSPLANTATION FOR MALIGNANCY: PARENT AND PROVIDER PER-
SPECTIVES AND PATTERNS OF CARE
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Lehmann, L.1,3, Wolfe, J.1,2,3 1Dana-Farber Cancer Institute, Boston,
MA; 2Dana-Farber Cancer Institute, Boston, MA; 3Children’s Hospital,
Boston,MA; 4PeytonManning Children’s Hospital at St. Vincent, Indian-
apolis, IN; 5Children’s Hospitals and Clinics of Minnesota, St. Paul and
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Background:The end-of-life (EOL) experience of childrenwho un-
dergo stem cell transplant (SCT), intensive therapy delivered with
curative intent, may differ from other children with cancer.
